Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Notes Payables (2023 - 2025)

Telix Pharmaceuticals has reported Notes Payables over the past 3 years, most recently at $13.1 million for Q4 2025.

  • Quarterly Notes Payables rose 5.57% to $13.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, up 5.57% year-over-year, with the annual reading at $13.1 million for FY2025, 11.45% up from the prior year.
  • Notes Payables was $13.1 million for Q4 2025 at Telix Pharmaceuticals, up from $12.4 million in the prior quarter.
  • Over five years, Notes Payables peaked at $13.1 million in Q4 2025 and troughed at $627554.8 in Q4 2023.
  • The 3-year median for Notes Payables is $12.4 million (2024), against an average of $8.7 million.
  • Year-over-year, Notes Payables skyrocketed 1878.89% in 2024 and then increased 5.57% in 2025.
  • A 3-year view of Notes Payables shows it stood at $627554.8 in 2023, then skyrocketed by 1878.89% to $12.4 million in 2024, then rose by 5.57% to $13.1 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Notes Payables are $13.1 million (Q4 2025), $12.4 million (Q4 2024), and $627554.8 (Q4 2023).